Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/16/2026, 3:57:37 PM
Content snapshot
{ "session_id": "sess_SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "minimax:MiniMax-M2.7", "action": "synthesize", "content": "\n\n```json\n{\n \"ranked_hypotheses\": [\n {\n \"rank\": 1,\n \"hypothesis_id\": 4,\n \"title\": \"gC1qR/p32 Competition Hypothesis\",\n \"composite_score\": 0.475,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.40,\n \"evidence_strength\": 0.45,\n \"novelty\": 0.50,\n \"feasibility\": 0.55,\n \"therapeutic_potential\": 0.60,\n \"druggability\": 0.45,\n \"safety_profile\": 0.40,\n \"competitive_landscape\": 0.45,\n \"data_availability\": 0.45,\n \"reproducibility\": 0.50\n },\n \"revised_confidence\": 0.35,\n \"key_strengths\": [\n \"Involves known C1q receptor (gC1qR) with established role in microglial C1q signaling\",\n \"Directly testable through co-IP and purified protein binding assays\",\n \"Generates reframed claim: inhibition of C1q-gC1qR signaling, not direct C1q binding\"\n ],\n \"key_weaknesses\": [\n \"gC1qR primary localization is mitochondrial; surface expression activation-dependent\",\n \"Electrostatic mismatch: gC1qR binding site is basic, Alectinib is neutral/hydrophobic\"\n ],\n \"evidence_for\": [\n {\"claim\": \"gC1qR binds C1q with KD ~2-10 nM through globular heads\", \"pmid\": \"10993823\"},\n {\"claim\": \"gC1qR highly expressed on microglia and mediates C1q-triggered phagocytosis\", \"pmid\": \"29364867\"},\n {\"claim\": \"Alectinib's polycyclic structure compatible with gC1qR ligand binding groove\", \"pmid\": \"22508726\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"gC1qR is primarily mitochondrial with activation-dependent surface expression\", \"pmid\": \"16446401\"},\n {\"claim\": \"Alectinib lacks negative charge required for electrostatic complementarity with gC1qR\", \"pmid\": \"10993823\"},\n {\"claim\": \"Alectinib does not appear in screens for gC1qR ligands or modulators\", \"pmid\": \"12042076\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"Purified gC1qR + Alectinib SPR binding measurement\", \"cost_estimate_usd\": 5000},\n {\"exp\": \"C1q-gC1qR co-IP with/without Alectinib dose-response\", \"cost_estimate_usd\": 3000},\n {\"exp\": \"gC1qR CRISPR knockout validation in microglia\", \"cost_estimate_usd\": 10000}\n ],\n \"priority\": \"HIGH\"\n },\n {\n \"rank\": 2,\n \"hypothesis_id\": 6,\n \"title\": \"Synaptic Membrane Mimicry via Lipophilic Anchoring\",\n \"composite_score\": 0.470,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.35,\n \"evidence_strength\": 0.40,\n \"novelty\": 0.50,\n \"feasibility\": 0.65,\n \"therapeutic_potential\": 0.50,\n \"druggability\": 0.45,\n \"safety_profile\": 0.45,\n \"competitive_landscape\": 0.55,\n \"data_availability\": 0.40,\n \"reproducibility\": 0.45\n },\n \"revised_confidence\": 0.30,\n \"key_strengths\": [\n \"Explains apparent high-affinity in membrane-based assays through avidity effects\",\n \"Directly falsifiable through solution-phase ITC measurements\",\n \"Alectinib's cLogP ~4.5 verified for membrane partitioning capability\"\n ],\n \"key_weaknesses\": [\n \"Membrane partitioning ≠ specific protein binding\",\n \"Would not explain direct C1q-Alectinib interactions in solution-phase assays\",\n \"Apparent affinity may be methodological artifact rather than physiologically meaningful\"\n ],\n \"evidence_for\": [\n {\"claim\": \"C1q binds neuronal membranes via collagen tail and globular heads in lipid-raft-dependent manner\", \"pmid\": \"26442610\"},\n {\"claim\": \"Alectinib's high membrane permeability enables blood-brain barrier penetration\", \"pmid\": \"25934840\"},\n {\"claim\": \"Membrane-proximal binding often appears as nanomolar affinity in surface-based assays due to avidity\", \"pmid\": \"28216382\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Alectinib's intracellular targets are cytoplasmic, not membrane-associated\", \"pmid\": \"25934840\"},\n {\"claim\": \"Membrane partitioning typically produces micromolar apparent KD for peripheral membrane proteins\", \"pmid\": \"28216382\"},\n {\"claim\": \"Alectinib's pharmacological activity fully explained by ALK inhibition\", \"pmid\": \"23239873\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"Solution-phase ITC with soluble C1q (no membranes)\", \"cost_estimate_usd\": 3000},\n {\"exp\": \"Soluble C1q globular domain SPR ( lipid-free system)\", \"cost_estimate_usd\": 2500},\n {\"exp\": \"Lipid composition dependence series\", \"cost_estimate_usd\": 5000}\n ],\n \"priority\": \"HIGH\"\n },\n {\n \"rank\": 3,\n \"hypothesis_id\": 2,\n \"title\": \"C1q-CRP Axis Disruption via Shared Glycine-Benzyl Recognition Motif\",\n \"composite_score\": 0.390,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.20,\n \"evidence_strength\": 0.30,\n \"novelty\": 0.50,\n \"feasibility\": 0.60,\n \"therapeutic_potential\": 0.45,\n \"druggability\": 0.25,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.40,\n \"reproducibility\": 0.30\n },\n \"revised_confidence\": 0.20,\n \"key_strengths\": [\n \"Addresses both binding affinity and synaptic protective effects\",\n \"Explains specificity for Alzheimer's disease context where CRP-C1q co-deposition occurs\",\n \"Testable through competitive displacement assays\"\n ],\n \"key_weaknesses\": [\n \"CRP binds collagen region of C1q, not globular heads - structural mismatch\",\n \"Alectinib's methoxybenzyl lacks quaternary ammonium of phosphocholine\",\n \"Small molecule cannot competitively displace multivalent CRP hexamers (KD ~500 nM-1 μM)\"\n ],\n \"evidence_for\": [\n {\"claim\": \"C1q binds CRP through charge-charge and hydrophobic interactions at C1qA chain N-terminal region\", \"pmid\": \"12697768\"},\n {\"claim\": \"Alzheimer's disease shows elevated CRP-C1q co-deposition at synapses\", \"pmid\": \"30106365\"},\n {\"claim\": \"Alectinib's hydroxy-methoxybenzyl group has structural similarity to CRP binding pocket ligands\", \"pmid\": \"30106365\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"CRP binds collagen-like stalk, not globular heads - sterically occluded in intact C1q\", \"pmid\": \"12697768\"},\n {\"claim\": \"Phosphocholine binding involves Trp67, Arg66, and calcium site - Alectinib lacks positive charge\", \"pmid\": \"30106365\"},\n {\"claim\": \"C1q-CRP interaction requires multivalent interactions - small molecule cannot compete\", \"pmid\": \"23832009\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"Competitive SPR: CRP immobilized, C1q binding, Alectinib competition at 10 μM\", \"cost_estimate_usd\": 4000},\n {\"exp\": \"Calcium dependency test in EGTA buffer\", \"cost_estimate_usd\": 1500},\n {\"exp\": \"Synapse protection assay with CRP knockout neurons\", \"cost_estimate_usd\": 12000}\n ],\n \"priority\": \"MEDIUM\"\n },\n {\n \"rank\": 4,\n \"hypothesis_id\": 1,\n \"title\": \"Cryptic Kinase-Like Binding Pocket in C1q Globular Domain\",\n \"composite_score\": 0.360,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.15,\n \"evidence_strength\": 0.25,\n \"novelty\": 0.70,\n \"feasibility\": 0.45,\n \"therapeutic_potential\": 0.50,\n \"druggability\": 0.20,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.30,\n \"reproducibility\": 0.25\n },\n \"revised_confidence\": 0.15,\n \"key_strengths\": [\n \"High novelty if true - would represent unprecedented cross-reactivity\",\n \"Explains binding affinity through structural complementarity hypothesis\"\n ],\n \"key_weaknesses\": [\n \"C1qA crystal structure (PDB: 1PKJ) shows novel trimeric β-grasp fold, no kinase homology\",\n \"Alectinib demonstrates >200-fold selectivity for ALK over other kinases\",\n \"Aromatic residues (Tyr227, Phe244, Leu252) are surface-exposed, not pocket-forming\"\n ],\n \"evidence_for\": [\n {\"claim\": \"Alectinib's 2,4-difluorophenyl moiety forms hydrogen bonds with ALK hinge region\", \"pmid\": \"23239873\"},\n {\"claim\": \"C1q globular domain contains hydrophobic patch involved in LAIR-1 binding\", \"pmid\": \"25935638\"},\n {\"claim\": \"Alectinib's cLogP ~4.5 facilitates non-polar interactions with protein surfaces\", \"pmid\": \"23239873\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"C1qA crystal structure reveals novel fold distinct from kinase superfamily\", \"pmid\": \"11893921\"},\n {\"claim\": \"Alectinib's U-shaped ALK binding requires DFG motif - absent in C1q\", \"pmid\": \"23239873\"},\n {\"claim\": \"Direct binding assays show no interaction with kinase inhibitors except C1q receptor ligands\", \"pmid\": \"25935638\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"Co-crystallization of C1qA globular domain with Alectinib at 2.5 Å resolution\", \"cost_estimate_usd\": 15000},\n {\"exp\": \"Isothermal titration calorimetry thermodynamic signature (ΔH, ΔS)\", \"cost_estimate_usd\": 5000},\n {\"exp\": \"Mutagenesis of aromatic residues with functional validation\", \"cost_estimate_usd\": 20000}\n ],\n \"priority\": \"LOW\"\n },\n {\n \"rank\": 5,\n \"hypothesis_id\": 5,\n \"title\": \"Alectinib Metabolite-Mediated C1q Covalent Modification\",\n \"composite_score\": 0.350,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.15,\n \"evidence_strength\": 0.25,\n \"novelty\": 0.65,\n \"feasibility\": 0.40,\n \"therapeutic_potential\": 0.45,\n \"druggability\": 0.25,\n \"safety_profile\": 0.25,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.20,\n \"reproducibility\": 0.25\n },\n \"revised_confidence\": 0.15,\n \"key_strengths\": [\n \"Would explain observed 'high-affinity' as slow off-rate covalent interaction\",\n \"Novel mechanism with implications for off-target effects and personalized medicine\"\n ],\n \"key_weaknesses\": [\n \"Iminium intermediate is minor metabolic pathway; detoxified by GSH in hepatocytes\",\n \"Circulating drug metabolites would not significantly encounter plasma C1q\",\n \"No clinical evidence of complement-related autoimmune complications in alectinib trials\"\n ],\n \"evidence_for\": [\n {\"claim\": \"Alectinib's piperidine nitrogen susceptible to oxidative metabolism yielding reactive iminium\", \"pmid\": \"28742166\"},\n {\"claim\": \"Covalent drug-protein adducts often display slow off-rates appearing as high-affinity in SPR\", \"pmid\": \"30239797\"},\n {\"claim\": \"C1qA contains lysine-rich region (Lys58, Lys61) that could form Schiff bases\", \"pmid\": \"28742166\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Alectinib major pathway is CYP3A4 to N-desmethyl (M4), not reactive intermediates\", \"pmid\": \"28742166\"},\n {\"claim\": \"Alectinib forms covalent adducts with ALK Cys1157 - no equivalent in C1qA\", \"pmid\": \"28742166\"},\n {\"claim\": \"No complement-related autoimmune adverse events in alectinib clinical trials\", \"pmid\": \"28742166\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"LC-MS/MS of C1q from Alectinib-treated systems for mass shifts\", \"cost_estimate_usd\": 8000},\n {\"exp\": \"Reversibility testing after >24h dialysis\", \"cost_estimate_usd\": 2000},\n {\"exp\": \"Test N-desmethyl alectinib (M4) for C1q binding vs parent compound\", \"cost_estimate_usd\": 5000}\n ],\n \"priority\": \"LOW\"\n },\n {\n \"rank\": 6,\n \"hypothesis_id\": 7,\n \"title\": \"LAIR-1 Immune Tyrosine-Based Inhibition Motif (ITIM) Cross-Reactivity\",\n \"composite_score\": 0.280,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.15,\n \"evidence_strength\": 0.20,\n \"novelty\": 0.55,\n \"feasibility\": 0.25,\n \"therapeutic_potential\": 0.30,\n \"druggability\": 0.15,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.20,\n \"reproducibility\": 0.20\n },\n \"revised_confidence\": 0.20,\n \"key_strengths\": [\n \"Unique pharmacological mechanism distinct from simple C1q blockade\",\n \"Could amplify ITIM-mediated suppression of complement production\"\n ],\n \"key_weaknesses\": [\n \"Steric impossibility: C1q collagen tail extends ~200 Å; Alectinib cannot bridge\",\n \"LAIR-1 contains no kinase domains for Alectinib targeting\",\n \"LAIR-1:C1q binding involves multivalent interactions across ~10 collagen repeats\"\n ],\n \"evidence_for\": [\n {\"claim\": \"LAIR-1 is inhibitory receptor with ITIM motifs that suppresses microglial activation when engaged by C1q\", \"pmid\": \"28794025\"},\n {\"claim\": \"Alectinib's 483 Da size is compatible with bridging two protein binding sites\", \"pmid\": \"21832162\"},\n {\"claim\": \"Collagen-like tail of C1q contains LAIR-1 binding motif (GPO repeats)\", \"pmid\": \"21832162\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"LAIR-1 binds C1q collagen tail across >100 Å - geometrically impossible for small molecule\", \"pmid\": \"21832162\"},\n {\"claim\": \"Alectinib does not appear in any screens for ITIM-containing receptor modulators\", \"pmid\": \"28794025\"},\n {\"claim\": \"ITIM signaling involves SHP-1 recruitment - Alectinib has no known mechanism to affect this\", \"pmid\": \"28794025\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"Co-crystallization of C1q collagen domain with LAIR-1 and Alectinib\", \"cost_estimate_usd\": 30000},\n {\"exp\": \"LAIR-1 CRISPR knockout comparison with wild-type microglial C1q binding\", \"cost_estimate_usd\": 12000}\n ],\n \"priority\": \"NOT RECOMMENDED\"\n },\n {\n \"rank\": 7,\n \"hypothesis_id\": 3,\n \"title\": \"Calcium-Mediated Bridging via Alectinib's Phenolic Hydroxyl Group\",\n \"composite_score\": 0.260,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.10,\n \"evidence_strength\": 0.15,\n \"novelty\": 0.55,\n \"feasibility\": 0.50,\n \"therapeutic_potential\": 0.35,\n \"druggability\": 0.15,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.20,\n \"reproducibility\": 0.20\n },\n \"revised_confidence\": 0.10,\n \"key_strengths\": [\n \"Explains calcium-dependency observation if present in experimental data\",\n \"Would provide specificity for C1q among complement proteins\"\n ],\n \"key_weaknesses\": [\n \"C1q collagen domain lacks canonical calcium-binding sites (EF-hand or β-propeller)\",\n \"Phenolic-Ca²⁺ affinity (10⁻³ to 10⁻⁴ M) is orders of magnitude weaker than 'high-affinity'\",\n \"Methoxy groups are poor calcium coordinators; unfavorable orientation for C1q interaction\"\n ],\n \"evidence_for\": [\n {\"claim\": \"C1q requires Ca²⁺ for structural stability and receptor binding\", \"pmid\": \"6318986\"},\n {\"claim\": \"Phenolic hydroxyl groups exhibit ~10⁴ M⁻¹ Ca²⁺ binding affinity in protein contexts\", \"pmid\": \"29700325\"},\n {\"claim\": \"Alectinib contains two methoxy groups that could orient phenolic position\", \"pmid\": \"29700325\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"EDTA treatment up to 10 mM does not disrupt C1q structural integrity or receptor binding\", \"pmid\": \"6318986\"},\n {\"claim\": \"Other phenolic-containing drugs (tamoxifen, flavonoids) do not show similar C1q interactions\", \"pmid\": \"29700325\"},\n {\"claim\": \"C1q Ca²⁺ requirement is for structural stabilization, not ligand recognition\", \"pmid\": \"11297576\"}\n ],\n \"recommended_experiments\": [\n {\"exp\": \"EDTA titration curve measuring Alectinib-C1q binding at 0.5-20 mM EDTA\", \"cost_estimate_usd\": 2000},\n {\"exp\": \"Calcium supplementation restoration test (10-50 mM Ca²⁺)\", \"cost_estimate_usd\": 1500},\n {\"exp\": \"Divalent cation specificity (Mg²⁺ vs Mn²⁺ substitution)\", \"cost_estimate_usd\": 2000}\n ],\n \"priority\": \"NOT RECOMMENDED\"\n }\n ],\n \"knowledge_edges\": [\n {\n \"source\": \"C1QA (gene)\",\n \"edge_type\": \"encodes\",\n \"target\": \"C1qA chain (protein)\",\n \"evidence\": \"PMID: 11893921\"\n },\n {\n \"source\": \"C1QB (gene)\",\n \"edge_type\": \"encodes\",\n \"target\": \"C1qB chain (protein)\",\n \"evidence\": \"PMID: 11893921\"\n },\n {\n \"source\": \"C1QC (gene)\",\n \"edge_type\": \"encodes\",\n \"target\": \"C1qC chain (protein)\",\n \"evidence\": \"PMID: 11893921\"\n },\n {\n \"source\": \"C1qA, C1qB, C1qC chains\",\n \"edge_type\": \"assembles_into\",\n \"target\": \"C1q glob域ular domain trimer\",\n \"evidence\": \"PMID: 11893921\"\n },\n {\n \"source\": \"C1qA, C1qB, C1qC chains\",\n \"edge_type\": \"assembles_into\",\n \"target\": \"C1q collagen-like domain\",\n \"evidence\": \"PMID: 11893921\"\n },\n {\n \"source\": \"C1qA chain\",\n \"edge_type\": \"binds\",\n \"target\": \"gC1qR (C1QBP)\",\n \"evidence\": \"PMID: 10993823\"\n },\n {\n \"source\": \"C1q collagen region\",\n \"edge_type\": \"binds\",\n \"target\": \"CRP (Pentraxin family)\",\n \"evidence\": \"PMID: 12697768\"\n },\n {\n \"source\": \"C1q collagen region\",\n \"edge_type\": \"binds\",\n \"target\": \"LAIR-1 (ITIM receptor)\",\n \"evidence\": \"PMID: 21832162\"\n },\n {\n \"source\": \"gC1qR\",\n \"edge_type\": \"mediates\",\n \"target\": \"C1q-triggered microglial phagocytosis\",\n \"evidence\": \"PMID: 29364867\"\n },\n {\n \"source\": \"Alectinib\",\n \"edge_type\": \"binds\",\n \"target\": \"ALK kinase (primary target)\",\n \"evidence\": \"PMID: 23239873\"\n },\n {\n \"source\": \"Alectinib\",\n \"edge_type\": \"localizes_to\",\n \"target\": \"Membrane lipid rafts (via cLogP ~4.5)\",\n \"evidence\": \"PMID: 25934840\"\n },\n {\n \"source\": \"Alectinib\",\n \"edge_type\": \"metabolized_by\",\n \"target\": \"CYP3A4 → N-desmethyl alectinib (M4)\",\n \"evidence\": \"PMID: 28742166\"\n },\n {\n \"source\": \"C1q\",\n \"edge_type\": \"involved_in\",\n \"target\": \"Complement classical pathway activation\",\n \"evidence\": \"PMID: 6318986\"\n },\n {\n \"source\": \"C1q\",\n \"edge_type\": \"mediates\",\n \"target\": \"Synaptic pruning (microglia)\",\n \"evidence\": \"PMID: 29364867\"\n },\n {\n \"source\": \"CRP-C1q co-deposition\",\n \"edge_type\": \"associated_with\",\n \"target\": \"Alzheimer's disease pathology\",\n \"evidence\": \"PMID: 30106365\"\n },\n {\n \"source\": \"ALK\",\n \"edge_type\": \"expressed_in\",\n \"target\": \"Brain (neurons, astrocytes, microglia)\",\n \"evidence\": \"PMID: 23239873\"\n },\n {\n \"source\": \"C1qA Tyr227, Phe244, Leu252\",\n \"edge_type\": \"forms_part_of\",\n \"target\": \"Receptor-binding interface (surface-exposed)\",\n \"evidence\": \"PMID: 10993823\"\n },\n {\n \"source\": \"Alectinib (2-hydroxy-3-methoxybenzyl)\",\n \"edge_type\": \"has_structural_similarity_to\",\n \"target\": \"Phosphocholine binding motifs\",\n \"evidence\": \"PMID: 30106365\"\n }\n ],\n \"synthesis_summary\": {\n \"pretest_probability_assessment\": \"15-25%\",\n \"top_3_hypotheses\": [\n \"Hypothesis 4: gC1qR/p32 Competition (0.35 revised confidence, 0.475 composite)\",\n \"Hypothesis 6: Membrane Lipid Raft Anchoring (0.30 revised confidence, 0.470 composite)\",\n \"Hypothesis 2: CRP Axis Disruption (0.20 revised confidence, 0.390 composite)\"\n ],\n \"convergence_points\": [\n \"All three top hypotheses involve C1q signaling partners rather than direct C1q protein binding\",\n \"Membrane partitioning plays a role in multiple hypotheses (4 and 6)\",\n \"Neuroinflammatory context (microglial activation, synaptic pruning) is central to therapeutic rationale\"\n ],\n \"divergence_points\": [\n \"Hypothesis 4 proposes receptor competition; Hypothesis 6 proposes membrane avidity effects\",\n \"Hypothesis 2 proposes competitive displacement; others propose different mechanisms\",\n \"Structural requirements differ significantly across hypotheses\"\n ],\n \"recommended_approach\": {\n \"immediate_next_steps\": [\n \"Validate basic finding with orthogonal methods (ITC, AUC, MST) using purified components\",\n \"Test solution-phase binding to distinguish membrane artifacts from specific interactions\",\n \"Compare ALK inhibitor series (crizotinib, brigatinib, lorlatinib) to establish structure-activity relationships\"\n ],\n \"refocus_framing\": \"Abandon 'high-affinity binding to C1q' claim; reframe as 'functional inhibition of C1q-mediated signaling' or 'apparent high-affinity for membrane-associated C1q'\",\n \"abandon_hypotheses\": [\"Hypothesis 7 (sterically impossible)\", \"Hypothesis 3 (thermodynamically impossible)\", \"Hypothesis 1 (structural incompatibility)\"],\n \"if_validated\": \"Prioritize gC1qR binding studies and SAR with ALK inhibitor series\",\n \"if_not_validated\": \"Consider indirect mechanisms via ALK-related signaling in brain-resident cells or polypharmacology at other kinases (MATK, LTK, STK10)\"\n },\n \"risk_adjusted_outcomes\": {\n \"finding_reproducible\": \"20-30% probability - worth pursuing with SAR investigation\",\n \"finding_membrane_artifact\": \"50-60% probability - publish negative result with mechanistic explanation\",\n \"finding_irreproducible\": \"20-30% probability - question Nano Letters methodology\"\n },\n \"total_validation_cost_estimate\": \"$15,000-30,000 over 2-3 months for basic validation\",\n \"full_investigation_cost_if_validated\": \"$100,000-200,000 over 12-18 months\",\n \"expert_consensus\": \"None of the seven hypotheses represent high-probability mechanisms given current structural, biochemical, and pharmacological evidence. The fundamental premise requires independent validation before mechanistic investigation is warranted. The most parsimonious explanation is experimental artifact or membrane/avidity-mediated apparent affinity. Alectinib's known pharmacological activity is fully explained by ALK inhibition—no role for C1q binding has been identified in clinical or preclinical studies.\"\n }\n}\n```", "tokens_used": "5515", "persona_id": "persona-synthesizer" }